Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.62 |
| ▸ | CNR1 | P21554 | 7/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3898514 | 0.91 | CNR2 (0.51) | CNR2CNR1 | |
| SCHEMBL13898588 | 0.88 | CNR2 (0.57) | CNR2CNR1ALDH1A1EPHX2 | |
| SCHEMBL3899250 | 0.83 | CNR2 (0.59) | CNR2CNR1 | |
| SCHEMBL14313787 | 0.82 | HTR4 (0.45) | CNR2CNR1ALDH1A1 | |
| SCHEMBL3901927 | 0.82 | CNR2 (0.57) | CNR2CNR1 | |
| SCHEMBL4327335 | 0.82 | CNR2 (0.59) | CNR2CNR1ALDH1A1EPHX2 | |
| SCHEMBL3897746 | 0.81 | LMNA (0.53) | CNR2ALDH1A1EPHX2 | |
| SCHEMBL3898512 | 0.80 | ALDH1A1 (0.50) | CNR2CNR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3901949 | 0.80 | CNR2 (0.42) | CNR2CNR1KMT2AALDH1A1 | |
| SCHEMBL3901192 | 0.80 | MAPT (0.44) | CNR2CNR1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009491-A1 | 1-(3-naphthalen-1-yl-imidazo[1,5-a]pyridin-1-yl)-butan-1-one; chronic pain, an inflammatory disorder, rheumatoid arthritis, multiple sclerosis, osteoporosis and osteoarthritis; cannabinoid receptor ligands | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-01-10 | — | — | US | claimed |
| US-7501438-B2 | Pyridoimidazole derivatives | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-03-10 | — | — | US | disclosed |
| US-7501438-B2 | Pyridoimidazole derivatives | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-03-10 | — | — | US | disclosed |
| US-7501438-B2 | Pyridoimidazole derivatives | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-03-10 | — | — | US | disclosed |
| US-20080009491-A1 | 1-(3-naphthalen-1-yl-imidazo[1,5-a]pyridin-1-yl)-butan-1-one; chronic pain, an inflammatory disorder, rheumatoid arthritis, multiple sclerosis, osteoporosis and osteoarthritis; cannabinoid receptor ligands | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-01-10 | — | — | US | disclosed |
| US-20080009491-A1 | 1-(3-naphthalen-1-yl-imidazo[1,5-a]pyridin-1-yl)-butan-1-one; chronic pain, an inflammatory disorder, rheumatoid arthritis, multiple sclerosis, osteoporosis and osteoarthritis; cannabinoid receptor ligands | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009491-A1 | 1-(3-naphthalen-1-yl-imidazo[1,5-a]pyridin-1-yl)-butan-1-one; chronic pain, an inflammatory disorder, rheumatoid arthritis, multiple sclerosis, osteoporosis and osteoarthritis; cannabinoid receptor ligands | CNR1, CNR2, OPRK1 | CNR2 2/4885CNR1 1/4885MEN1 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.